Immunoprecise Antibodies Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Immunoprecise Antibodies Ltd (IPA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Immunoprecise Antibodies Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 18M vs 121,591M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+170.7% annualized vs trailing 12 months), vs decelerating (-9.9%) for its tracked peer group.
- Growth: Immunoprecise Antibodies Ltd generated -36.6% revenue growth year over year in Q4 2025, vs 1.3% for its tracked competitors combined.
- Profitability: Its -14.8% net margin compares with 1.8% for the peer group.
- Peer revenue share: Immunoprecise Antibodies Ltd accounted for 0.0% of combined revenue among its tracked peer group, down from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.01M compares with $0.50M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
IPA Sales vs. its Competitors, Q4 2025
Immunoprecise Antibodies Ltd reported revenue contraction of 36.56 % year on year in Q4 2025, below its competitors' combined revenue growth of 1.29 %.
With a net margin of -14.83 %, Immunoprecise Antibodies Ltd reported lower profitability than its competitors (1.82 %).
Immunoprecise Antibodies Ltd generated 0.04 % of the combined sales of its peer group, down from 0.07 % a year earlier.
Immunoprecise Antibodies Ltd vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Immunoprecise Antibodies Ltd and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Immunoprecise Antibodies Ltd | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Immunoprecise Antibodies Ltd's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -36.6% for Immunoprecise Antibodies Ltd. Immunoprecise Antibodies Ltd's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Immunoprecise Antibodies Ltd's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Immunoprecise Antibodies Ltd | - | No | No | Yes |
| Competitors combined (17) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
IPA Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Teva Pharmaceutical Industries Limited | 282.9% | Outperformed |
| 2 | Puma Biotechnology Inc | 282.9% | Outperformed |
| 3 | Charles River Laboratories International inc | 282.9% | Outperformed |
| 4 | Therapeuticsmd Inc | 282.9% | Outperformed |
| 5 | Viatris Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Immunoprecise Antibodies Ltd's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Immunoprecise Antibodies Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Immunoprecise Antibodies Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Immunoprecise Antibodies Ltd | 69.11 | 17.60 |
| Thermo Fisher Scientific Inc | 252,135.31 | 46,336.00 |
| Amgen Inc | 230,460.16 | 38,095.00 |
| Teva Pharmaceutical Industries Limited | 46,378.65 | 14,105.00 |
| Viatris Inc | 21,079.00 | 14,737.30 |
| Charles River Laboratories International inc | 14,212.30 | 3,998.99 |
| SUBTOTAL | 589,066.05 | 126,030.79 |
Sign in to see all competitors of Immunoprecise Antibodies Ltd .
Sources: Immunoprecise Antibodies Ltd's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Immunoprecise Antibodies Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Immunoprecise Antibodies Ltd's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Curia Inc. | Named by the company | 85% |
| Aldevron LLC | Named by the company | 85% |
| Lake Pharma Inc. | Named by the company | 85% |
| Genovac GmbH | Named by the company | 85% |
| Antibody Solutions | Named by the company | 85% |
| Abveris Inc. | Named by the company | 85% |
| Genscript Biotech Corp | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Immunoprecise Antibodies Ltd's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Immunoprecise Antibodies Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Thermo Fisher Scientific Inc | Clinical Research 19.98 % |
| Amgen Inc | Reportable 100.00 % |
| Teva Pharmaceutical Industries Limited | United States Segment 41.09 % |
| Viatris Inc | Developed Markets 57.61 % |
| Charles River Laboratories International inc | Discovery and Safety Assessment 59.94 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Immunoprecise Antibodies Ltd .
Immunoprecise Antibodies Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Immunoprecise Antibodies Ltd | 69 | 13,773 | -16,982 |
| Thermo Fisher Scientific Inc | 252,135 | 370,688 | 55,912 |
| Amgen Inc | 230,460 | 2,930,385 | 672,538 |
| Teva Pharmaceutical Industries Limited | 46,379 | 415,464 | 20,884 |
| Viatris Inc | 21,079 | 491,243 | -13,690 |
| Charles River Laboratories International inc | 14,212 | 202,994 | -11,995 |
| PEERS TOTAL | 588,997 | 499,822 | 60,990 |
Sign in to see all peers for Immunoprecise Antibodies Ltd .
Immunoprecise Antibodies Ltd's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Thermo Fisher Scientific Inc | North America 51.27 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Charles River Laboratories International inc | United States 54.61 % |
| Catalent Inc | North America 64.32 % |
| Bio rad Laboratories Inc | UNITED STATES 40.98 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Immunoprecise Antibodies Ltd .
Immunoprecise Antibodies Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Immunoprecise Antibodies Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Immunoprecise Antibodies Ltd ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 824, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,054,271 | 19.27 % |
| 2 | Johnson and Johnson | 662,243 | 12.10 % |
| 3 | Beone Medicines Ltd | 543,752 | 9.94 % |
| 4 | Abbvie Inc | 473,291 | 8.65 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Immunoprecise Antibodies Ltd | 53 | 0.00 % |
Market cap and industry share for the rest of Immunoprecise Antibodies Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-09-03.
Immunoprecise Antibodies Ltd's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 64.89 % (avg) | -64.9 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -7.21 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 3.26 % | 4.92 % (avg) | -1.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Immunoprecise Antibodies Ltd's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 0.9x | 4.5x | -3.6x |
| Return on Equity | -126.84 % | industry aggregate | -142.13 % |
| Return on Invested Capital | - | -2.95 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Immunoprecise Antibodies Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 824 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 3.26 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Immunoprecise Antibodies Ltd's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Immunoprecise Antibodies Ltd's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Immunoprecise Antibodies Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+170.7% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 142.1 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (37.50 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-9.9% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Immunoprecise Antibodies Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Immunoprecise Antibodies Ltd | 1.20 | 2.08 | - |
| Thermo Fisher Scientific Inc | 0.32 | 1.62 | 0.78 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Teva Pharmaceutical Industries Limited | 0.24 | 1.00 | 2.15 |
| Viatris Inc | 0.18 | 1.47 | 0.96 |
| Charles River Laboratories International inc | 0.18 | 1.34 | 0.78 |
Sign in to see all peers for Immunoprecise Antibodies Ltd .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Immunoprecise Antibodies Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Immunoprecise Antibodies Ltd | Q1 2025 | -6.3 % | - |
| Thermo Fisher Scientific Inc | Q2 2026 | +10.5 % | +7.6 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Teva Pharmaceutical Industries Limited | Q2 2026 | -0.8 % | - |
| Viatris Inc | Q2 2026 | +4.9 % | - |
| Charles River Laboratories International inc | Q2 2026 | -2.7 % | - |
| PEERS TOTAL | +7.0 % | +24.8 % |
Sign in to see all peers for Immunoprecise Antibodies Ltd .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Immunoprecise Antibodies Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Immunoprecise Antibodies Ltd | Q1 2025 | -17.5 % | -46.4 % |
| Thermo Fisher Scientific Inc | Q2 2026 | +142.5 % | +53.1 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Teva Pharmaceutical Industries Limited | Q2 2026 | -4.1 % | - |
| Viatris Inc | Q2 2026 | +2.3 % | -0.2 % |
| Charles River Laboratories International inc | Q2 2026 | - | -11.9 % |
Sign in to see all peers for Immunoprecise Antibodies Ltd .
Immunoprecise Antibodies Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Immunoprecise Antibodies Ltd | - | - | - |
| Thermo Fisher Scientific Inc | 6.36% | 7.71% | 13.37% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Teva Pharmaceutical Industries Limited | 1.77% | 2.66% | 9.11% |
| Viatris Inc | - | - | - |
| Charles River Laboratories International inc | - | - | - |
Sign in to see all peers for Immunoprecise Antibodies Ltd .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Immunoprecise Antibodies Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Immunoprecise Antibodies Ltd | - | 3.93 |
| Thermo Fisher Scientific Inc | 36.58 | 5.44 |
| Amgen Inc | 26.31 | 6.05 |
| Teva Pharmaceutical Industries Limited | 65.41 | 3.29 |
| Viatris Inc | - | 1.43 |
| Charles River Laboratories International inc | - | 3.55 |
| PEERS AVERAGE | 38.36 | 4.67 |
Sign in to see all peers for Immunoprecise Antibodies Ltd .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.